Beta Bionics
company
About
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $63M
- Industries
- Biotechnology,Diabetes,Medical Device
- Founded date
- Oct 21, 2015
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$125M
Beta Bionics has raised a total of
$125M
in funding over 2 rounds. Their latest funding was raised on
Feb 17, 2022 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 17, 2022 | Series C | $57M | 1 | — | — | Detail |
| Jan 8, 2019 | Series B | $63M | 1 | — | — | Detail |
| Dec 31, 2015 | Series A | $5M | 1 |
Novo Nordisk
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Beta Bionics is funded by 2 investors.
Novo Nordisk
and Dexcom
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Novo Nordisk
|
— | Series C |
Dexcom
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
